PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION lobbying for PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Nov 3, 2026

Expenses

$50,000

What this organization spent lobbying with its own staff. Reported using IRS section 162(e) definitions (method C): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

New Jersey

Official filing document

Lobbyists on this filing 1

GIL ROTH

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 6

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Pharmacy

Discussed issues related to biopharma supply chain tariff implementation, onshoring/friendshoring initiatives, robustness and transparency of biopharmaceutical supply chains (incl. CLEAR LABELS Act), drug shortages, and workforce development

Health Issues

Discussed issues related to biopharma supply chain tariff implementation, onshoring/friendshoring initiatives, robustness and transparency of biopharmaceutical supply chains (incl. CLEAR LABELS Act), drug shortages, and workforce development

Manufacturing

Discussed issues related to biopharma supply chain tariff implementation, onshoring/friendshoring initiatives, robustness and transparency of biopharmaceutical supply chains (incl. CLEAR LABELS Act), drug shortages, and workforce development

Tariff (miscellaneous tariff bills)

Discussed issues related to biopharma supply chain tariff implementation, onshoring/friendshoring initiatives, robustness and transparency of biopharmaceutical supply chains (incl. CLEAR LABELS Act), drug shortages, and workforce development